24.3% Below Target

The consensus Wall Street price target for CHKP is $152.1, representing 24.3% upside from the current price of $122.33. With 63 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

CHKP has a consensus rating of "Hold" based on 63 Wall Street analysts. The rating breakdown is mixed, with 31 Hold ratings making up the largest segment. The consensus 12-month price target of $152.1 implies 24.3% upside from current levels.

With a forward P/E of 11.7367x, CHKP trades at a relatively low valuation. The consensus target of $152.1 implies 24.3% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $220 for CHKP, while the most conservative target is $120. The consensus of $152.1 represents the median expectation. Our quantitative valuation model projects a bull case target of $196 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CHKP is heavily covered by Wall Street, with 63 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 27 have Buy ratings, 31 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CHKP stock forecast based on 63 Wall Street analysts shows a consensus price target of $152.1, with estimates ranging from $120 (bear case) to $220 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $149, with bear/bull scenarios of $94/$196.

Our quantitative valuation model calculates CHKP's fair value at $149 (base case), with a bear case of $94 and bull case of $196. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 61/100.

CHKP trades at a forward P/E ratio of 11.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are very optimistic on CHKP, with a "Hold" consensus rating and $152.1 price target (24.3% upside). 27 of 63 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CHKP analyst price targets range from $120 to $220, a 66% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $152.1 consensus represents the middle ground. Our model's $94-$196 range provides an independent fundamental perspective.